Clinical trial
Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by…
NCT00017784 · Hoffmann-La Roche, Industry · Unknown status
Key facts
| NCT number | NCT00017784 |
|---|---|
| Title | Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection |
| Official title | Open-Label Safety Study of Valganciclovir in Patients With CMV Retinitis and AIDS Who Have Complications Due to IV Treatment |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Unknown status |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cytomegalovirus Retinitis, HIV Infections |
| Intervention type | Drug |
| Interventions | Valganciclovir |
| Enrollment | 500 |
| First posted | Aug 31, 2001 |
| Last update posted | Jun 24, 2005 |
| Countries | Puerto Rico, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: